— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.
— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.
— Net product sales were $1.28 billion.
— EYLEA net product sales in the US were $1.22 billion.
— Sanofi and Bayer collaboration revenues were $748 million.
— R&D expenses totaled $683 million.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
What to look for when Halliburton Company (HAL) reports Q4 2024 results?
Halliburton Company (NYSE: HAL) is expected to report fourth-quarter results on Wednesday, January 22, at 6:45 am ET. The oilfield service provider is currently recovering from a rough patch, marked
McCormick (MKC) is set to report Q4 2024 earnings results next week, a few points to note
Shares of McCormick & Company, Incorporated (NYSE: MKC) rose over 1% on Thursday. The stock has gained 12% in the past 12 months. The company is scheduled to report its fourth quarter
PNC Financial Q4 2024 profit more than doubles; revenue up 4%
The PNC Financial Services Group, Inc. (NYSE: PNC) reported a sharp increase in profit for the fourth quarter of 2024. Revenues grew by 4%. Net income attributable to common shareholders
Comments
Comments are closed.